MOREPENLAB

Morepen Laboratories Share Price

₹51.76 -0.65 (-1.24%)

22 Feb, 2025 21:38

SIP TrendupStart SIP in MOREPENLAB

Start SIP

Performance

  • Low
  • ₹52
  • High
  • ₹54
  • 52 Week Low
  • ₹39
  • 52 Week High
  • ₹101
  • Open Price₹52
  • Previous Close₹52
  • Volume3,461,054

Investment Returns

  • Over 1 Month -23.17%
  • Over 3 Month -29.32%
  • Over 6 Month -25.77%
  • Over 1 Year -2.62%
SIP Lightning

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,836
  • P/B Ratio
  • 2.6
  • Average True Range
  • 3.43
  • EPS
  • 2.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.4
  • RSI
  • 31.52
  • MFI
  • 31.24

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹51.76
-0.65 (-1.24%)
pointer
  • stock-down_img
  • Bearish Moving Average 15
  • stock-up_img
  • Bullish Moving Average 1
  • 20 Day
  • ₹57.59
  • 50 Day
  • ₹65.06
  • 100 Day
  • ₹69.37
  • 200 Day
  • ₹67.27

Resistance and Support

52.56 Pivot Speed
  • R3 56.56
  • R2 55.49
  • R1 53.63
  • S1 50.70
  • S2 49.63
  • S3 47.77

What's your outlook on Morepen Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Morepen Laboratories Ltd. is a leading pharmaceutical company in India, specializing in Active Pharmaceutical Ingredients (APIs), formulations, diagnostics, and over-the-counter (OTC) products. It exports to over 75 countries, with a strong focus on APIs like Loratadine.

Morepen Laboratories has an operating revenue of Rs. 1,768.80 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-06 Quarterly Results
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-21 Audited Results
2024-01-31 Quarterly Results

Morepen Laboratories F&O

Morepen Laboratories Shareholding Pattern

35.65%
0%
0.94%
2.22%
0.68%
48.34%
12.17%

About Morepen Laboratories

  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • Chairman & Managing Director
  • Mr. Sushil Suri
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹51 As on 22 February, 2025 | 21:24

The Market Cap of Morepen Laboratories is ₹2836.2 Cr As on 22 February, 2025 | 21:24

The P/E ratio of Morepen Laboratories is 22.5 As on 22 February, 2025 | 21:24

The PB ratio of Morepen Laboratories is 2.6 As on 22 February, 2025 | 21:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23